Sorilux (Calcipotriene) Patent Expiration, LOE Window & CMS Spending

Sorilux (Calcipotriene) by Mayne: FDA Orange Book LOE 2028-05-07, 2 AB generics, $504K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN022563 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-05-07
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$504K
2024 Medicare Part D Spend$265K
2024 Medicaid Spend$239K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel